Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)19

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)11

Views

Views
May 20240
June 20247
July 20241
August 20243
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States10
 

Top cities views

Views
Ashburn6
Chicago1
Fort Worth1